| Original language | English (US) |
|---|---|
| Pages (from-to) | 143-144 |
| Number of pages | 2 |
| Journal | Contraception |
| Volume | 102 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2020 |
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynecology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Contraception, Vol. 102, No. 3, 09.2020, p. 143-144.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Oral contraceptive generations – Time to stop using a marketing myth to define nomenclature
AU - Creinin, Mitchell D.
AU - Jensen, Jeffrey T.
N1 - Funding Information: This commentary is adapted, with permission, from Creinin MD, Jensen JT. Reproduction and hormonal contraception (Ch. 2). In: Jensen JT, Creinin MD, editors. Speroff and Darney's Clinical Guide to Contraception, 6th ed. Wolters Kluwer, 2019, p. 59–63. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Disclosures: Dr. Creinin serves on an Advisory Board for Lupin, Merck & Co., and TherapeuticsMD and is a consultant for Danco, Estetra, Mayne, and Medicines360. The Department of Obstetrics and Gynecology, University of California, Davis, receives contraceptive research funding from Daré, HRA Pharma, Medicines360, Merck & Co. and Sebela. Dr. Jensen has received payments for consulting from Abbvie, Cooper Surgical, Bayer Healthcare, Merck, Sebela, and TherapeuticsMD. OHSU has received research support from Abbvie, Bayer Healthcare, Daré, Estetra SPRL, Medicines360, Merck, and Sebela. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU. Funding Information: Disclosures: Dr. Creinin serves on an Advisory Board for Lupin, Merck & Co., and TherapeuticsMD and is a consultant for Danco, Estetra, Mayne, and Medicines360. The Department of Obstetrics and Gynecology, University of California, Davis, receives contraceptive research funding from Daré, HRA Pharma, Medicines360, Merck & Co. and Sebela. Dr. Jensen has received payments for consulting from Abbvie, Cooper Surgical, Bayer Healthcare, Merck, Sebela, and TherapeuticsMD. OHSU has received research support from Abbvie, Bayer Healthcare, Daré, Estetra SPRL, Medicines360, Merck, and Sebela. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU.
PY - 2020/9
Y1 - 2020/9
UR - http://www.scopus.com/inward/record.url?scp=85087345016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087345016&partnerID=8YFLogxK
U2 - 10.1016/j.contraception.2020.05.017
DO - 10.1016/j.contraception.2020.05.017
M3 - Article
C2 - 32504633
AN - SCOPUS:85087345016
SN - 0010-7824
VL - 102
SP - 143
EP - 144
JO - Contraception
JF - Contraception
IS - 3
ER -